- Home
- AIIO vs HOWL Comparison
AIIO vs HOWL Comparison
Compare AIIO & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AIIO | HOWL |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United Arab Emirates | United States |
| Employees | 68 | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.5M | 30.7M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | AIIO | HOWL |
|---|---|---|
| Price | $0.70 | $0.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | ★ 2.0M | 307.1K |
| Earning Date | 05-02-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.40 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.07 | $0.53 |
| 52 Week High | $2.82 | $2.23 |
Technical Indicators
Market Signals| Indicator | AIIO | HOWL |
|---|---|---|
| Relative Strength Index (RSI) | 66.92 | 56.02 |
| Support Level | $0.17 | $0.79 |
| Resistance Level | $0.73 | $1.03 |
| Average True Range (ATR) | 0.09 | 0.09 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 56.57 | 41.46 |
Price Performance
Historical ComparisonAbout AIIO Robo.ai Inc. Class B Ordinary Shares
Robo.ai Inc is a pioneering smart electric vehicle company which aims to integrate avant-garde design, life-style personalization, IoT connectivity, and autonomous driving technology into a passenger-centric green premium mobility solution to the world. Geographically, the company operates in The United States, The United Arab Emirates, Mainland China.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.